SEC sues over suspected insider trading around Sanofi’s Bioverativ buy

7 years ago

by David Miller

957 Views

Written by David Miller

Did insider trading occur around Sanofi’s $11.6 billion deal for Bioverativ? The Securities and Exchange Commission thinks it may have—and it’s suing on that suspicion.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!